CMPXHealthcare · BiotechnologyThe 15 Wall Street analysts covering Compass Therapeutics, Inc. hold a median 12-month price target of $6 — +686.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Compass Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (70): Smaller than most of the companies we track.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CMPX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +686.1% from it.
Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Citizens | Maintains | Market Outperform | $10 → $4.00 |
| 23 Sept 2026 | Craig-Hallum | Maintains | Buy | $15 → $8.00 |
| 23 Sept 2026 | Guggenheim | Maintains | Buy | $8.00 → $4.00 |
| 23 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $12 |
| 23 Sept 2026 | Wedbush | Downgrade | Neutral | $5.00 → $1.00 |
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | $4.00 → $6.00 |
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 28 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 Apr 2026 | Canaccord Genuity | Maintains | Buy | $13 → $7.00 |
| 28 Apr 2026 | Citizens | Reiterates | Market Outperform | — |
| 28 Apr 2026 | Citizens | Reiterates | Market Outperform | $10 |
| 27 Apr 2026 | D. Boral Capital | Maintains | Buy | $30 |
| 27 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | $24 |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 6 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | William Blair | Initiates | Outperform | — |
| 3 Dec 2025 | Canaccord Genuity | Initiates | Buy | — |
| 3 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CMPX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Compass Therapeutics, Inc. returned −80.4% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 74% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Compass Therapeutics, Inc. has a market value of $137.5M and an enterprise value of −$25.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$73.4M.
Diluted earnings per share, trailing twelve months: $−0.40.
Free cash flow in the twelve months to 30 June 2026: −$56.4M.
Trailing P/E: −1.8×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Compass Therapeutics, Inc. employs 39 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Compass Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Compass Therapeutics announced that it granted stock options to a new employee under its 2025 Inducement Plan. The grant was made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Why it matters — CMPX watchers may note the equity-based inducement grant as a company employment and compensation disclosure.
Compass Therapeutics experienced a major setback after tovecimig failed to demonstrate an overall survival benefit in biliary tract cancer. The company plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial, with a financial runway extending into 2028.
Why it matters — A CMPX watcher would care because the failed survival data and FDA's guidance against the planned submission could jeopardize tovecimig's approval path and potentially force the company to raise capital from a weakened position.
Compass Therapeutics shares traded lower on Tuesday after FDA feedback raised new questions about the timing and requirements for its tovecimig cancer-drug program.
Why it matters — FDA feedback on trial timing and requirements introduces uncertainty around the clinical path for tovecimig, a key focus for CMPX investors.
Compass Therapeutics announced that the FDA recommended the company conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer. This regulatory update follows feedback received from the FDA.
Why it matters — The FDA's requirement for an additional survival-benefit trial before a BLA submission could delay the regulatory pathway for tovecimig in biliary tract cancer, a key development program for CMPX.
Compass Therapeutics expects feedback from the FDA this quarter on the Phase 2/3 COMPANION-002 data for tovecimig in biliary tract cancer, ahead of a potential BLA filing later this year. The tovecimig data was also selected for an oral presentation at the 2026 ESMO Congress in October.
Why it matters — A CMPX watcher would care because the expected FDA feedback and potential BLA filing are key near-term regulatory milestones for tovecimig, the company's lead bispecific antibody candidate.
The 15 Wall Street analysts covering Compass Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $1 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Compass Therapeutics, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compass Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Compass Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +686.1% from the last close, and Ticker Nerd's factor model ranks Compass Therapeutics, Inc. 30 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Compass Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMPX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $12 over the next 12 months.
Compass Therapeutics, Inc. returned -80.4% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Compass Therapeutics announced that it granted stock options to a new employee under its 2025 Inducement Plan. The grant was made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses. Its current pipeline includes bispecific and monoclonal antibody programs such as tovecimig, CTX-471, CTX-8371, and CTX-10726, reflecting a platform built around antibody discovery and engineering. Compass Therapeutics uses proprietary technologies to identify and optimize therapeutic leads and to create modular, manufacturable bispecific candidates. The company plays a specialized role in the biotechnology market by advancing immuno-oncology research into clinical development, with a focus on solid tumors and other cancer indications.
CEO Dr. Thomas J. Schuetz M.D., Ph.D. · 39 employees · United States · https://www.compasstherapeutics.com
